| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01303679 Details | 2023-09-06 Interventional | 3 | 117 | Bevacizumab Exemestane Paclitaxel Breast Neoplasm… First Line Meta… | Not reveal any significant difference between the 2 treatment arms - | |||
| NCT01044745 Details | 2023-09-06 Interventional | 2 | 20 | Antilymphocyte … Busulfan Cyclophosphamid… Fludarabine Fludarabine pho… Immunosuppressi… Mycophenolic Ac… Rituximab Tacrolimus Thymoglobulin Blast Crisis Burkitt Lymphom… Graft vs Host D… Leukemia Leukemia, Lymph… Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Leukemia, T-Cel… Leukemia-Lympho… Lymphoma Lymphoma, B-Cel… Lymphoma, B-Cel… Lymphoma, Extra… Lymphoma, Folli… Lymphoma, Large… Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… Lymphoma, T-Cel… Lymphoma, T-Cel… Lymphomatoid Gr… Mycoses Mycosis Fungoid… Myelodysplastic… Plasmablastic L… Precursor Cell … Preleukemia Recurrence Sezary Syndrome Syndrome Waldenstrom Mac… Accelerated Pha… Adult Acute Lym… Adult Acute Mye… Adult Nasal Typ… Blastic Phase C… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Contiguous Stag… Extranodal Marg… Graft Versus Ho… Nodal Marginal … Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Noncontiguous S… Previously Trea… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Cutan… Recurrent Grade… Recurrent Grade… Recurrent Grade… Recurrent Mantl… Recurrent Margi… Recurrent Mycos… Recurrent Small… Refractory Chro… Relapsing Chron… Secondary Myelo… Splenic Margina… Stage I Adult B… Stage I Adult D… Stage I Adult D… Stage I Adult D… Stage I Adult I… Stage I Adult L… Stage I Adult T… Stage I Chronic… Stage I Cutaneo… Stage I Grade 1… Stage I Grade 2… Stage I Grade 3… Stage I Mantle … Stage I Margina… Stage I Mycosis… Stage I Small L… Stage II Adult … Stage II Chroni… Stage II Cutane… Stage II Mycosi… Stage III Adult… Stage III Adult… Stage III Adult… Stage III Adult… Stage III Adult… Stage III Adult… Stage III Adult… Stage III Chron… Stage III Cutan… Stage III Grade… Stage III Grade… Stage III Grade… Stage III Mantl… Stage III Margi… Stage III Mycos… Stage III Small… Stage IV Adult … Stage IV Adult … Stage IV Adult … Stage IV Adult … Stage IV Adult … Stage IV Adult … Stage IV Adult … Stage IV Chroni… Stage IV Cutane… Stage IV Grade … Stage IV Grade … Stage IV Grade … Stage IV Mantle… Stage IV Margin… Stage IV Mycosi… Stage IV Small … Untreated Adult… Untreated Adult… Waldenström Ma… de Novo Myelody… | Study was closed to accrual for safety related to the frequency of BK infections. - | |||
| NCT05245916 Details | 2023-09-05 Interventional | 1 | 0 | Rituximab Neoplasms Advanced Malign… | Due to the company's development strategy adjustment - | |||
| NCT04675827 Details | 2023-09-05 Interventional | 2 | - | Ado-Trastuzumab… Maytansine Pertuzumab Trastuzumab Breast Neoplasm… ER-Negative Bre… HER2-positive B… Node-negative B… PR-Negative Bre… | Serious concerns on the slow recruitment of the study that impacts the robustness of the
scientific rationale and the study financial provision. It aims to assess carefully the
situation and to evaluate the potential solutions to overcome the issues. - | |||
| NCT04322305 Details | 2023-09-05 Interventional | 2 | - | Pregabalin Alcohol Drinkin… Alcoholism Alcohol Use Dis… | U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research
that included a pause of human subjects research as of June 23, 2023. This study will resume
recruitment after OHRP has approved the resumption of research. - | |||
| NCT05708989 Details | 2023-09-01 Interventional | 4 | - | Dexmedetomidine Ropivacaine Hypospadias Phimosis Chordee Penile Torsion | Transitioning to new clinic - | |||
| NCT05473715 2022-000690-73 Details | 2023-09-01 Interventional | 4 | 3 | Aflibercept Macular Degener… Neovascular (We… | Study terminated due to administrative reasons not related to efficacy or safety. - | |||
| NCT05320380 Details | 2023-09-01 Interventional | 1/2 | 0 | Cortisone Cytarabine Daunorubicin Fludarabine Fludarabine pho… Hydrocortisone Hydrocortisone … Hydrocortisone … Hydrocortisone … Methotrexate Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Acute Disease Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Precursor Cell … Precursor T-Cel… Recurrence Recurrent Acute… Recurrent B Acu… Recurrent Mixed… Recurrent T Acu… Refractory Acut… Refractory B Ac… Refractory Mixe… Refractory T Ac… | Withdrawn per CS0150757 - | |||
| NCT04192019 Details | 2023-09-01 Interventional | 1 | 0 | Glucagon Glucagon-Like P… Diabetes Mellit… Diabetes Mellit… Hypoglycemia Type 1 Diabetes | Prioritization of other projects - | |||
| NCT05416320 Details | 2023-08-31 Interventional | 1 | 0 | Calcipotriene Alopecia Alopecia Areata Central Centrif… | The IRB was closed without enrolling any participants - | |||
| NCT04811573 2019-005037-37 Details | 2023-08-31 Interventional | 1 | 20 | Apremilast Thalidomide Healthy | due to company decision This trial was prematurely discontinued due to sponsor decision. The planned recruitment amount was not reached. The planned statistical analyses of the pharmacokinetic parameters were not performed. | |||
| NCT04605094 Details | 2023-08-31 Interventional | 2 | 194 | Benralizumab Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | The study did not meet the primary endpoint. The study was terminated as the study did not support the continued development of benralizumab for the indication of AD. | |||
| NCT04190056 Details | 2023-08-31 Interventional | 2 | 1 | Pembrolizumab Tamoxifen Vorinostat Breast Neoplasm… Anatomic Stage … Prognostic Stag… | Change in practice patterns The study closed early due to change in practice patterns | |||
| NCT04422392 Details | 2023-08-30 Interventional | 2 | 93 | Antibodies Carboplatin Paclitaxel Pemetrexed Carcinoma, Non-… Lung Neoplasms Non Small Cell … | since the CheckMate816 study is published in NEJM, enrolling patients becomes difficult - | |||
| NCT03919799 Details | 2023-08-30 Interventional | 2 | 36 | Belumosudil Scleroderma, Di… Scleroderma, Sy… Sclerosis Diffuse Cutaneo… System; Scleros… | Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety
concerns. The study was terminated early by the Sponsor due to slow enrollment and strategic consideration and was not driven due to any safety concerns. | |||
| NCT03362515 Details | 2023-08-30 Interventional | 2 | 18 | Furosemide Nasal Polyps | The study was terminated prematurely due to low enrollment numbers and the development of
better drugs to treat polyps (ie. Biologics) which were not available when the study began. - | |||
| NCT04480086 2020-001226-65 Details | 2023-08-29 Interventional | 1 | 1 | Navitoclax Primary Myelofi… Myelofibrosis (… | Strategic considerations - | |||
| NCT04258683 Details | 2023-08-29 Interventional | 2 | 0 | Pembrolizumab Multiple Myelom… Neoplasms, Plas… | Study terminated due to changing treatment landscape - | |||
| NCT03317496 2017-001741-27 Details | 2023-08-29 Interventional | 1/2 | 67 | Antibodies, Mon… Avelumab Carboplatin Cisplatin Gemcitabine Pemetrexed Carcinoma, Non-… Non-small Cell … Urothelial Canc… | The study was terminated since there was no need for further safety or efficacy data to be
collected. The participants having benefit from the investigational treatments have been moved
to a continuation study (NCT05059522). The study was terminated since there was no need for further safety or efficacy data to be collected. The subjects having benefit from the investigational treatments have been moved to a continuation study NCT05059522 | |||
| NCT01465334 Details | 2023-08-29 Interventional | 2 | [1 Refs] | 30 | Alemtuzumab Methylprednisol… Methylprednisol… Methylprednisol… Ofatumumab Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… CLL SLL | Terminated early due to change in practice. - |